Cargando…

Bioinformatics roadmap for therapy selection in cancer genomics

Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez‐Santos, María José, García‐Martín, Santiago, Fustero‐Torre, Coral, Di Domenico, Tomás, Gómez‐López, Gonzalo, Al‐Shahrour, Fátima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627786/
https://www.ncbi.nlm.nih.gov/pubmed/35811332
http://dx.doi.org/10.1002/1878-0261.13286
_version_ 1784823047393378304
author Jiménez‐Santos, María José
García‐Martín, Santiago
Fustero‐Torre, Coral
Di Domenico, Tomás
Gómez‐López, Gonzalo
Al‐Shahrour, Fátima
author_facet Jiménez‐Santos, María José
García‐Martín, Santiago
Fustero‐Torre, Coral
Di Domenico, Tomás
Gómez‐López, Gonzalo
Al‐Shahrour, Fátima
author_sort Jiménez‐Santos, María José
collection PubMed
description Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored treatments for each cancer patient according to epidemiological, clinical and omics data. This discipline relies on bioinformatics tools designed to compute scores to prioritise available drugs, with the aim of helping clinicians in treatment selection. In this review, we describe the current approaches for therapy selection depending on which type of tumour heterogeneity is being targeted and the available next‐generation sequencing data. We cover intertumour heterogeneity studies and individual treatment selection using genomics variants, expression data or multi‐omics strategies. We also describe intratumour dissection through clonal inference and single‐cell transcriptomics, in each case providing bioinformatics tools for tailored treatment selection. Finally, we discuss how these therapy selection workflows could be integrated into the clinical practice.
format Online
Article
Text
id pubmed-9627786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96277862022-11-03 Bioinformatics roadmap for therapy selection in cancer genomics Jiménez‐Santos, María José García‐Martín, Santiago Fustero‐Torre, Coral Di Domenico, Tomás Gómez‐López, Gonzalo Al‐Shahrour, Fátima Mol Oncol Reviews Tumour heterogeneity is one of the main characteristics of cancer and can be categorised into inter‐ or intratumour heterogeneity. This heterogeneity has been revealed as one of the key causes of treatment failure and relapse. Precision oncology is an emerging field that seeks to design tailored treatments for each cancer patient according to epidemiological, clinical and omics data. This discipline relies on bioinformatics tools designed to compute scores to prioritise available drugs, with the aim of helping clinicians in treatment selection. In this review, we describe the current approaches for therapy selection depending on which type of tumour heterogeneity is being targeted and the available next‐generation sequencing data. We cover intertumour heterogeneity studies and individual treatment selection using genomics variants, expression data or multi‐omics strategies. We also describe intratumour dissection through clonal inference and single‐cell transcriptomics, in each case providing bioinformatics tools for tailored treatment selection. Finally, we discuss how these therapy selection workflows could be integrated into the clinical practice. John Wiley and Sons Inc. 2022-08-20 2022-11 /pmc/articles/PMC9627786/ /pubmed/35811332 http://dx.doi.org/10.1002/1878-0261.13286 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Jiménez‐Santos, María José
García‐Martín, Santiago
Fustero‐Torre, Coral
Di Domenico, Tomás
Gómez‐López, Gonzalo
Al‐Shahrour, Fátima
Bioinformatics roadmap for therapy selection in cancer genomics
title Bioinformatics roadmap for therapy selection in cancer genomics
title_full Bioinformatics roadmap for therapy selection in cancer genomics
title_fullStr Bioinformatics roadmap for therapy selection in cancer genomics
title_full_unstemmed Bioinformatics roadmap for therapy selection in cancer genomics
title_short Bioinformatics roadmap for therapy selection in cancer genomics
title_sort bioinformatics roadmap for therapy selection in cancer genomics
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627786/
https://www.ncbi.nlm.nih.gov/pubmed/35811332
http://dx.doi.org/10.1002/1878-0261.13286
work_keys_str_mv AT jimenezsantosmariajose bioinformaticsroadmapfortherapyselectionincancergenomics
AT garciamartinsantiago bioinformaticsroadmapfortherapyselectionincancergenomics
AT fusterotorrecoral bioinformaticsroadmapfortherapyselectionincancergenomics
AT didomenicotomas bioinformaticsroadmapfortherapyselectionincancergenomics
AT gomezlopezgonzalo bioinformaticsroadmapfortherapyselectionincancergenomics
AT alshahrourfatima bioinformaticsroadmapfortherapyselectionincancergenomics